Paper I — 2019 February (2010 Scheme) — Q10

Paper I

2019 February (2010 Scheme) · 40 marks · 120 min

Question

Dantrolene in malignant hyperthermia

Q101 marksShort Answers★✓

Answer

Malignant hyperthermia is caused by excessive, uncontrolled release of calcium from the sarcoplasmic reticulum in skeletal muscle (via a defective ryanodine receptor, RyR1), triggered by certain anaesthetic agents (halothane, succinylcholine), leading to sustained muscle contraction/rigidity, hypermetabolism, and severe hyperthermia. Dantrolene directly binds to the ryanodine receptor and inhibits calcium release from the sarcoplasmic reticulum, reducing excitation-contraction coupling and reversing the muscle rigidity and hypermetabolic state — making it the specific, life-saving treatment for malignant hyperthermia.

Related Concepts

1. 1Skeletal Muscle Relaxants

Other Years Asked

1. 1(2023 January (Supplementary) (2019 Scheme)Short Essay · 8 marks
2. 2Read the clinical problem and answer the following questions: 30 years old man was admitted in emergency ward with acute abdominal pain. After diagnosed with acute appendicitis, he was taken for surgery. On the operation table, after administration of a skeletal muscle relaxant, patient developed difficulty in breathing and went in for apnoea.2015 September (Supplementary) (2010 Scheme)Essay · 6 marks
3. 3Read the clinical problem and answer the following questions: A 50 years old man was administered succinylcholine for endotracheal intubation. The patient developed prolonged muscle paralysis and apnea. (2+2+2)  What could be the cause of apnea in this patient  How will you treat the apnea  Name two muscle relaxants that you can use in this patient in future2021 May (Supplementary) (2010 Scheme)Essay · 6 marks
4. 4Atracurium2020 February (Supplementary) (2010 Scheme)Short Note · 3 marks
5. 5Mechanism of action of diazepam2014 March (2010 Scheme)Short Answer · 1 mark
6. 6Mechanism of action of pancuronium.2016 October (Supplementary) (2010 Scheme)Short Answer · 1 mark
7. 7Diazepam2023 March (Supplementary) (2010 Scheme)Short Answer · 1 mark
8. 8Flumazenil2013 April (2010 Scheme)Short Answer · 1 mark
9. 9Centrally acting muscle relaxants2015 September (Supplementary) (2010 Scheme)Short Answer · 1 mark
10. 10Mechanism of action of diazepam.2016 February (2010 Scheme)Short Answer · 1 mark
11. 11Mechanism of action of dantrolene sodium.2014 September (Supplementary) (2010 Scheme)Short Answer · 1 mark
12. 12Dantrolene sodium in malignant hyperthermia2023 March (Supplementary) (2010 Scheme)Short Answer · 1 mark
13. 13d-Tubocurarine2021 May (Supplementary) (2010 Scheme)Short Answer · 1 mark
14. 14Dantrolene in malignant hyperthermia.2025 August (Supplementary) (2010 Scheme)Short Answer · 1 mark
15. 15Diazepam2024 March (Supplementary) (2010 Scheme)Short Answer · 1 mark
16. 16Peripherally acting skeletal muscle relaxants2013 September (Supplementary) (2010 Scheme)Short Answer · 1 mark
17. 17Uses of diazepam2017 February (2010 Scheme)Short Answer · 1 mark
18. 18Competitive neuromuscular blockers2018 July (Supplementary) (2010 Scheme)Short Answer · 1 mark
19. 19Centrally acting skeletal muscle relaxants2022 May (Supplementary) (2010 Scheme)Short Answer · 0.3 marks
20. 20Depolarizing neuromuscular blocking agents2022 October (Supplementary) (2010 Scheme)Short Answer · 0.3 marks
21. 21Skeletal muscle relaxants2022 July (Supplementary) (2019 Scheme)Short Answer · 0.2 marks
22. 22Centrally acting skeletal muscle relaxants2024 March (Supplementary) (2019 Scheme)Short Answer · 0.2 marks